文献速递糖尿病

酮单酯饮品降低2型糖尿病成人餐后血糖浓度:一项随机对照试验

A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-03-14

该随机、安慰剂对照、双盲交叉试验纳入10例2型糖尿病成人,采用双葡萄糖示踪法评估餐前摄入0.5 g/kg体质量酮单酯(KME)或安慰剂后混合餐耐量试验的葡萄糖动力学。KME使血浆β-羟丁酸从0.3±0.03 mmol/l升至峰值4.3±1.2 mmol/l,2小时餐后血糖降低约18%、4小时降低约12%,主要因餐后2小时葡萄糖出现率降低28%(均p<0.05)。结论认为KME似乎延缓葡萄糖吸收,从而降低餐后血糖。

要点

  • KME使2小时餐后血糖降低约18%、4小时降低约12%(均p<0.05)。
  • KME使餐后2小时葡萄糖出现率降低28%(p<0.05)。
  • KME对餐后内源性葡萄糖生成无影响,未观察到不良反应。

核心结论

  • KME摄入似乎延缓2型糖尿病成人的葡萄糖吸收,从而降低餐后血糖浓度。
  • 未来有必要探索KME补充在2型糖尿病中的治疗潜力。

研究设计与样本

  • 随机、安慰剂对照、双盲交叉试验,采用计算机生成的随机数字进行随机化。
  • 纳入10例2型糖尿病参与者(年龄59±1.7岁,50%女性,BMI 32±1 kg/m2,HbA1c 54±2 mmol/mol [7.1±0.2%])。
  • 研究在皇家学院(Royal College)埃克塞特大学营养生理学研究部进行,地点为英国埃克塞特。
  • 采用双葡萄糖示踪法,在混合餐耐量试验前摄入0.5 g/kg体质量的KME或口味匹配的非热量安慰剂。
  • 主要结局指标为内源性葡萄糖生成;次要结局指标包括总葡萄糖出现率、外源性葡萄糖出现率、葡萄糖消失率、血糖、血清胰岛素、β-羟丁酸和NEFA水平及能量消耗。

主要发现

  • KME使平均±SEM血浆β-羟丁酸从0.3±0.03 mmol/l升至峰值4.3±1.2 mmol/l。
  • KME使2小时餐后血糖浓度降低约18%,4小时餐后血糖浓度降低约12%。
  • KME使餐后2小时葡萄糖出现率降低28%(均p<0.05)。
  • KME摄入后血浆NEFA浓度受抑制,对照组与KME组之间血浆胰岛素浓度无差异。
  • 餐后内源性葡萄糖生成不受KME影响(对照组与KME组平均±SEM分别为0.76±0.15和0.88±0.10 mg kg-1 min-1),未观察到KME摄入的不良反应。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 未来有必要探索KME补充在2型糖尿病中的治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of the present study was to conduct a randomised, placebo-controlled, double-blind, crossover trial to determine whether pre-meal ketone monoester ingestion reduces postprandial glucose concentrations in individuals with type 2 diabetes. METHODS: In this double-blind, placebo-controlled, crossover design study, ten participants with type 2 diabetes (age 59±1.7 years, 50% female, BMI 32±1 kg/m2, HbA1c 54±2 mmol/mol [7.1±0.2%]) were randomised using computer-generated random numbers. The study took place at the Nutritional Physiology Research Unit, University of Exeter, Exeter, UK. Using a dual-glucose tracer approach, we assessed glucose kinetics after the ingestion of a 0.5 g/kg body mass ketone monoester (KME) or a taste-matched non-caloric placebo before a mixed-meal tolerance test. The primary outcome measure was endogenous glucose production. Secondary outcome measures were total glucose appearance rate and exogenous glucose appearance rate, glucose disappearance rate, blood glucose, serum insulin, β-OHB and NEFA levels, and energy expenditure. RESULTS: Data for all ten participants were analysed. KME ingestion increased mean ± SEM plasma beta-hydroxybutyrate from 0.3±0.03 mmol/l to a peak of 4.3±1.2 mmol/l while reducing 2 h postprandial glucose concentrations by ~18% and 4 h postprandial glucose concentrations by ~12%, predominately as a result of a 28% decrease in the 2 h rate of glucose appearance following meal ingestion (all p<0.05). The reduction in blood glucose concentrations was associated with suppressed plasma NEFA concentrations after KME ingestion, with no difference in plasma insulin concentrations between the control and KME conditions. Postprandial endogenous glucose production was unaffected by KME ingestion (mean ± SEM 0.76±0.15 and 0.88±0.10 mg kg-1 min-1 for the control and KME, respectively). No adverse effects of KME ingestion were observed. CONCLUSIONS/INTERPRETATION: KME ingestion appears to delay glucose absorption in adults with type 2 diabetes, thereby reducing postprandial glucose concentrations. Future work to explore the therapeutic potential of KME supplementation in type 2 diabetes is warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT05518448. FUNDING: This project was supported by a Canadian Institutes of Health Research (CIHR) Project Grant (PJT-169116) and a Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (RGPIN-2019-05204) awarded to JPL and an Exeter-UBCO Sports Health Science Fund Project Grant awarded to FBS and JPL.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Monteyne AJ, Falkenhain K, Whelehan G, et al. A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial. Diabetologia. 2024. PMID: 38483543. doi:10.1007/s00125-024-06122-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。